Background
Thymosin β4’s primary molecular role is G-actin sequestration — it maintains the pool of monomeric actin required for cytoskeletal dynamics and cell motility. Because wound healing fundamentally depends on coordinated cell migration (keratinocytes, fibroblasts, endothelial cells), Tβ4 was hypothesized to be a critical pro-healing signal.
This study systematically tested topical and systemic Tβ4 in both normal and diabetic wound models, the latter being particularly relevant because diabetic wounds are highly resistant to standard therapies.
Methods
Study 1 (Normal rats): Full-thickness excisional wounds treated with:
- Tβ4 (10 µg/wound) topically in methylcellulose vehicle, twice weekly
- Vehicle control
Study 2 (Diabetic db/db mice): Same design in leptin receptor-deficient diabetic mice — a validated model of human diabetic wound healing impairment.
Outcomes: Wound area (planimetry), histology (collagen density, vascularity), keratinocyte migration rate.
Key Findings
Normal Rat Wounds:
- Tβ4-treated wounds closed 22% faster than controls at day 7
- Histology: 1.8× greater collagen fiber density; more organized matrix architecture
- Keratinocyte migration front significantly advanced at wound margins
Diabetic Mouse Wounds:
- Vehicle control wounds showed characteristic diabetic delay (minimal closure at day 14)
- Tβ4 treatment largely rescued the healing deficit: 85% closure by day 14 vs. 40% in vehicle
- Microvessel density in wound granulation tissue: 2.3× greater with Tβ4
Mechanism:
- Tβ4 stimulated keratinocyte migration via actin remodeling at the leading edge
- VEGF upregulation in wound margins contributed to angiogenic response
- Anti-inflammatory effect reduced the excessive neutrophil infiltration that impairs diabetic wound healing
Clinical Significance
The diabetic wound finding is particularly important because:
- Diabetic foot ulcers affect ~15% of diabetic patients and account for 80% of lower limb amputations — a massive unmet medical need
- Impaired angiogenesis is the core defect in diabetic wounds; Tβ4’s VEGF-driven neovascularization directly addresses this
- Cell migration rescue: Diabetic keratinocytes have impaired migration; Tβ4’s actin sequestration activity may restore normal cytoskeletal dynamics
These findings helped motivate clinical development of Tβ4 (RGN-352/TB-500) for wound healing applications.
Limitations
- Animal models; human wound healing is more complex and slower
- Topical formulation used — SC bioavailability and systemic distribution data are from separate studies
- db/db mouse model has limitations as a human T2D wound analog
- Long-term scar quality was not assessed